VarmX

VarmX to present at the American Society of Hematology (ASH) Annual Meeting & Exposition

Poster presentation highlights Phase 1 data showing VMX-C001 has no effect on the anticoagulant function of heparin in healthy subjects 1 December 2025 -- Leiden, The Netherlands -- VarmX, a biotech company developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and treatment of inherited coagulation disorders, will...
Emmy Noetherweg 2, 
 2333 BK Leiden, 
 The Netherlands